BioCentury
ARTICLE | Clinical News

Concert Pharmaceuticals preclinical data

January 21, 2013 8:00 AM UTC

In in vitro efficacy assays, CTP-221 produced a 2.7-fold increase in IL-2 induction in anti-CD3 stimulated peripheral blood mononuclear cells (PBMCs) compared to racemic lenalidomide. Additionally, CTP-221 produced a 3.7-fold greater inhibition of tumor necrosis factor (TNF) alpha production in LPS-stimulated whole blood and a 2.6-fold greater inhibition of proliferation of human MM cells. Data were presented at the American Society of Hematology meeting in Atlanta. Concert plans to submit an IND for the deuterated S-enantiomer of lenalidomide this year. ...